Eyenovia (EYEN) to Release Earnings on Tuesday

Eyenovia (NASDAQ:EYEN) will be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Eyenovia to post earnings of ($0.13) per share for the quarter.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Monday, August 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Eyenovia had a negative return on equity of 547.46% and a negative net margin of 116,506.25%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $1.38 million. On average, analysts expect Eyenovia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eyenovia Stock Up 2.6 %

EYEN stock opened at $0.50 on Friday. The company has a debt-to-equity ratio of 3.72, a quick ratio of 0.27 and a current ratio of 0.46. Eyenovia has a one year low of $0.37 and a one year high of $2.57. The company has a fifty day moving average of $0.51 and a 200-day moving average of $0.72. The stock has a market capitalization of $31.99 million, a PE ratio of -0.61 and a beta of 1.75.

Insider Activity at Eyenovia

In related news, CEO Michael M. Rowe bought 50,000 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $28,500.00. Following the completion of the acquisition, the chief executive officer now owns 82,927 shares in the company, valued at $47,268.39. This trade represents a 100.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 7.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on EYEN shares. William Blair upgraded shares of Eyenovia to a “strong-buy” rating in a research note on Friday, August 30th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Eyenovia in a report on Tuesday, August 13th.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.